CA2421114C - 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith - Google Patents
5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith Download PDFInfo
- Publication number
- CA2421114C CA2421114C CA2421114A CA2421114A CA2421114C CA 2421114 C CA2421114 C CA 2421114C CA 2421114 A CA2421114 A CA 2421114A CA 2421114 A CA2421114 A CA 2421114A CA 2421114 C CA2421114 C CA 2421114C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- disease
- hydroxy
- carboxy
- phenylazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 22
- 230000003115 biocidal effect Effects 0.000 title abstract description 13
- 238000000034 method Methods 0.000 title description 14
- 230000003110 anti-inflammatory effect Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 77
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 208000028774 intestinal disease Diseases 0.000 claims abstract description 16
- 150000002148 esters Chemical class 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims description 16
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 9
- 229960004889 salicylic acid Drugs 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 8
- APJAZCDUSIQPFZ-UHFFFAOYSA-N 5-[[4-(3-carboxypropanoylsulfamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid Chemical compound C1=CC(S(=O)(=O)NC(=O)CCC(=O)O)=CC=C1N=NC1=CC=C(O)C(C(O)=O)=C1 APJAZCDUSIQPFZ-UHFFFAOYSA-N 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 7
- 239000011593 sulfur Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- SSOBRAVLVWANQI-UHFFFAOYSA-N 5-[[4-[(2-carboxyacetyl)sulfamoyl]phenyl]diazenyl]-2-hydroxybenzoic acid Chemical compound C1=CC(S(=O)(=O)NC(=O)CC(=O)O)=CC=C1N=NC1=CC=C(O)C(C(O)=O)=C1 SSOBRAVLVWANQI-UHFFFAOYSA-N 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 9
- 238000003776 cleavage reaction Methods 0.000 abstract description 5
- 238000011321 prophylaxis Methods 0.000 abstract description 5
- 230000007017 scission Effects 0.000 abstract description 5
- 208000019423 liver disease Diseases 0.000 abstract description 3
- 208000007386 hepatic encephalopathy Diseases 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 35
- 239000000203 mixture Substances 0.000 description 32
- 238000009472 formulation Methods 0.000 description 28
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 26
- 229960004963 mesalazine Drugs 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 10
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 239000012954 diazonium Substances 0.000 description 9
- 150000001989 diazonium salts Chemical class 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000002207 metabolite Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 9
- 229960001940 sulfasalazine Drugs 0.000 description 9
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 229960002211 sulfapyridine Drugs 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- QWKKYJLAUWFPDB-UHFFFAOYSA-N 4-nitrobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 QWKKYJLAUWFPDB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- CJBSUYFZVHLWST-UHFFFAOYSA-N methyl 4-[(4-nitrophenyl)sulfonylamino]-4-oxobutanoate Chemical compound COC(=O)CCC(=O)NS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 CJBSUYFZVHLWST-UHFFFAOYSA-N 0.000 description 2
- BDKRBZCIUFGVQQ-UHFFFAOYSA-N methyl 5-[(4-aminophenyl)sulfonylamino]-5-oxopentanoate Chemical compound COC(=O)CCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 BDKRBZCIUFGVQQ-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- -1 nausea Chemical compound 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 2
- 229960004110 olsalazine Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- UFEXYOGJTIYVLC-UHFFFAOYSA-N 5-[[4-(4-carboxybutanoylsulfamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid Chemical compound C1=CC(S(=O)(=O)NC(=O)CCCC(=O)O)=CC=C1N=NC1=CC=C(O)C(C(O)=O)=C1 UFEXYOGJTIYVLC-UHFFFAOYSA-N 0.000 description 1
- MMTSFNTVGNSWFD-UHFFFAOYSA-N 5-[[4-[(2-carboxyacetyl)sulfamoyl]phenyl]diazenyl]-2-hydroxybenzoic acid ethyl 3-[(4-aminophenyl)sulfonylamino]-3-oxopropanoate Chemical compound C(C)OC(CC(=O)NS(=O)(=O)C1=CC=C(C=C1)N)=O.C(=O)(O)CC(=O)NS(=O)(=O)C1=CC=C(C=C1)N=NC=1C=CC(=C(C(=O)O)C1)O MMTSFNTVGNSWFD-UHFFFAOYSA-N 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017914 Gastroenteritis salmonella Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 206010053982 Microsporidia infection Diseases 0.000 description 1
- 201000000090 Microsporidiosis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048249 Yersinia infections Diseases 0.000 description 1
- 208000025079 Yersinia infectious disease Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000008951 colonic inflammation Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ZFLWJSNOJKIMCN-UHFFFAOYSA-N ethyl 3-[(4-aminophenyl)sulfonylamino]-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 ZFLWJSNOJKIMCN-UHFFFAOYSA-N 0.000 description 1
- CVBGXQSXNXAKEH-UHFFFAOYSA-N ethyl 3-[(4-nitrophenyl)sulfonylamino]-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 CVBGXQSXNXAKEH-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 208000027136 gram-positive bacterial infections Diseases 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- SRXOJMOGPYFZKC-UHFFFAOYSA-N methyl 4-chloro-4-oxobutanoate Chemical compound COC(=O)CCC(Cl)=O SRXOJMOGPYFZKC-UHFFFAOYSA-N 0.000 description 1
- JCAZSWWHFJVFPP-UHFFFAOYSA-N methyl 5-chloro-5-oxopentanoate Chemical compound COC(=O)CCCC(Cl)=O JCAZSWWHFJVFPP-UHFFFAOYSA-N 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000000361 pesticidal effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22868200P | 2000-08-29 | 2000-08-29 | |
| US60/228,682 | 2000-08-29 | ||
| PCT/US2001/041910 WO2002018330A1 (en) | 2000-08-29 | 2001-08-28 | 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2421114A1 CA2421114A1 (en) | 2002-03-07 |
| CA2421114C true CA2421114C (en) | 2010-12-07 |
Family
ID=22858177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2421114A Expired - Lifetime CA2421114C (en) | 2000-08-29 | 2001-08-28 | 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6458776B1 (https=) |
| EP (1) | EP1313699B1 (https=) |
| JP (1) | JP5112595B2 (https=) |
| AT (1) | ATE460394T1 (https=) |
| AU (1) | AU2001285489A1 (https=) |
| CA (1) | CA2421114C (https=) |
| DE (1) | DE60141520D1 (https=) |
| IL (2) | IL154537A0 (https=) |
| MX (1) | MXPA03001786A (https=) |
| WO (1) | WO2002018330A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1313697T3 (da) | 2000-08-29 | 2006-04-10 | Nobex Corp | Immunregulatoriske forbindelser, derivater deraf samt anvendelse deraf |
| US8048924B2 (en) | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
| CA2496547A1 (en) * | 2002-08-29 | 2004-03-11 | University Of Southampton | Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases |
| WO2004078172A2 (en) * | 2003-03-06 | 2004-09-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sod mimic multifunctional compounds for treating inflammatory bowel disease |
| SE523093C2 (sv) * | 2003-03-25 | 2004-03-30 | Sven Kindblom | Stötdämpare för höjdreglering |
| ES2398237T3 (es) | 2003-07-23 | 2013-03-14 | Novartis Ag | Uso de calcitonina en osteoartritis |
| JP2007520495A (ja) | 2004-02-06 | 2007-07-26 | ボロディー トーマス ユリウス | 下痢型過敏性腸症候群におけるアミノサリチル酸の使用法 |
| US20080306029A1 (en) * | 2004-05-28 | 2008-12-11 | Salix Pharmaceuticals, Inc. | Prevention, Treatment, and Amelioration of Radiation Induced Enteritis |
| DK1773767T3 (en) | 2004-07-07 | 2016-03-21 | Biocon Ltd | Synthesis of azo bound in immune regulatory relations |
| US20060270635A1 (en) * | 2005-05-27 | 2006-11-30 | Wallace John L | Derivatives of 4- or 5-aminosalicylic acid |
| US8541398B2 (en) * | 2005-05-27 | 2013-09-24 | Antibe Therapeutics Inc. | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
| US7666907B2 (en) * | 2005-05-27 | 2010-02-23 | Antibe Therapeutics Inc. | Salts of trimebutine and N-desmethyl trimebutine |
| WO2006125293A1 (en) * | 2005-05-27 | 2006-11-30 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
| US7498355B2 (en) * | 2005-05-27 | 2009-03-03 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
| US7741359B2 (en) * | 2005-05-27 | 2010-06-22 | Antibe Therapeutics Inc. | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
| EP2529729A1 (en) * | 2005-08-24 | 2012-12-05 | Salix Pharmaceuticals, Inc. | Balsalazide formulations and manufacture thereof |
| US8921344B2 (en) * | 2006-11-03 | 2014-12-30 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| US7452872B2 (en) | 2005-08-24 | 2008-11-18 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| AU2006318815B2 (en) | 2005-11-17 | 2010-08-19 | Novartis Ag | Pharmaceutical composition |
| WO2007103448A2 (en) * | 2006-03-09 | 2007-09-13 | Salix Pharmaceuticals, Inc. | Rifaximin anti-rectal dysfunction preparation |
| US7271253B1 (en) * | 2006-08-10 | 2007-09-18 | Apotex Pharmachem Inc. | Safe process for the preparation of balsalazide |
| JPWO2008114831A1 (ja) * | 2007-03-20 | 2010-07-08 | 国立大学法人 岡山大学 | スルホンアミド基を有する抗菌剤 |
| US20090098088A1 (en) * | 2007-10-10 | 2009-04-16 | The Procter & Gamble Company | Methods And Kits For The Treatment Of Diverticular Conditions |
| MX2010011995A (es) * | 2008-05-01 | 2010-12-02 | Procter & Gamble | Metodos y estuches para el tratamiento de condiciones y trastornos inflamatorios del intestino. |
| CN105348184B (zh) * | 2015-11-26 | 2020-12-29 | 苏州统华药品有限公司 | 一种柳氮磺吡啶的制备方法 |
| US11744859B2 (en) | 2017-07-07 | 2023-09-05 | Epicentrx, Inc. | Compositions and methods for parenteral administration of therapeutic agents |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2270676A (en) * | 1936-08-20 | 1942-01-20 | Winthrop Chem Co Inc | Sulphonic acid amide compound |
| US2396145A (en) * | 1940-12-14 | 1946-03-05 | Pharmscia Ab | Heterocyclic sulphonamido azo compounds |
| BE791889A (fr) * | 1971-11-26 | 1973-05-24 | Pharmacia Ab | Nouveaux derives de la pyridine |
| JPS5353449A (en) * | 1976-10-22 | 1978-05-15 | Sofuia Kk | Picture type pachinko game machine |
| US4412992A (en) * | 1980-07-21 | 1983-11-01 | Biorex Laboratories Limited | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith |
| SU1011126A1 (ru) * | 1981-07-14 | 1983-04-15 | Всесоюзный научно-исследовательский и испытательный институт медицинской техники | Средство дл лечени сахарного диабета |
| CS142691A3 (en) * | 1991-05-15 | 1992-11-18 | Vyzk Ustav Farm Biochem Sp | Process for preparing 5-//4-/(4',6'-dimethyl-2-pyrimidinyl)sulfamoyl/phenyl/azo/-acetylsalicylic acid |
| SE9700934D0 (sv) * | 1997-03-14 | 1997-03-14 | Astra Ab | New formulation |
-
2001
- 2001-08-28 AT AT01964654T patent/ATE460394T1/de not_active IP Right Cessation
- 2001-08-28 DE DE60141520T patent/DE60141520D1/de not_active Expired - Lifetime
- 2001-08-28 MX MXPA03001786A patent/MXPA03001786A/es unknown
- 2001-08-28 JP JP2002523448A patent/JP5112595B2/ja not_active Expired - Fee Related
- 2001-08-28 CA CA2421114A patent/CA2421114C/en not_active Expired - Lifetime
- 2001-08-28 IL IL15453701A patent/IL154537A0/xx unknown
- 2001-08-28 AU AU2001285489A patent/AU2001285489A1/en not_active Abandoned
- 2001-08-28 EP EP01964654A patent/EP1313699B1/en not_active Expired - Lifetime
- 2001-08-28 WO PCT/US2001/041910 patent/WO2002018330A1/en not_active Ceased
- 2001-08-29 US US09/942,510 patent/US6458776B1/en not_active Expired - Lifetime
-
2003
- 2003-02-19 IL IL154537A patent/IL154537A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL154537A0 (en) | 2003-09-17 |
| IL154537A (en) | 2013-07-31 |
| JP5112595B2 (ja) | 2013-01-09 |
| DE60141520D1 (de) | 2010-04-22 |
| ATE460394T1 (de) | 2010-03-15 |
| US20020111334A1 (en) | 2002-08-15 |
| CA2421114A1 (en) | 2002-03-07 |
| AU2001285489A1 (en) | 2002-03-13 |
| JP2004507521A (ja) | 2004-03-11 |
| WO2002018330A1 (en) | 2002-03-07 |
| US6458776B1 (en) | 2002-10-01 |
| MXPA03001786A (es) | 2003-06-04 |
| EP1313699B1 (en) | 2010-03-10 |
| EP1313699A1 (en) | 2003-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2421114C (en) | 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith | |
| US6583128B2 (en) | Immunoregulatory compounds and derivatives and methods of treating diseases therewith | |
| AU2001285311A1 (en) | Immunoregulatory compounds, derivatives thereof and their use | |
| US8569466B2 (en) | Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers | |
| CN100455574C (zh) | 噻唑啉酸衍生物 | |
| JP2008542291A (ja) | 網膜疾患を処置するための組成物および方法 | |
| HRP20050517A2 (en) | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobial agents | |
| JP5783910B2 (ja) | 小分子を用いるリン酸管理 | |
| CN113166067A (zh) | 用于治疗胃肠疾病的化合物和方法 | |
| HK1054221B (en) | Immunoregulatory compounds, derivatives thereof and their use | |
| HK1089749B (en) | Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract | |
| US20210052537A1 (en) | Colitis ameliorating agent | |
| US20160362402A1 (en) | Novel compounds having anti-allodynic and antihyperalgesic activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20210830 |